A Comprehensive, Customizable Genomic and Immune Profiling Solution - from Discovery through Commercialization. Your mission is to move across the drug development continuum with speed and efficiency. Our goal is to help you by delivering insight on emerging and actionable biomarkers targeted for drug development.

Chimeric antigen receptor (CAR) T-cell therapies are effective immunotherapeutic tools for combating cancer with genetically modified cancer-specific receptors. The effectiveness of cancer treatment is likely to fuel the global market growth of CAR T-cell therapy in the years to come.

Explore our global immunology and immunotoxicology capabilities, customizable to meet your needs: From early biomarker discovery and preclinical toxicology in a range of species, all the way through to early and late-stage clinical trials.

Give your device a healthy start by gaining the experienced and knowledgeable advice and specialized testing your device or combination product demands. Gain the insights and clarity you need to move forward with greater confidence.

The preclinical stage of medical device development comes with a unique set of challenges. You need to determine that the materials that make up your device are safe and biologically compatible and that your prototype will perform the way you intend.

Whether you need to test the materials your device is made of or the efficacy of your device or combination product, Labcorp offers the solutions and experience required to move forward with confidence.

Precision medicine, a new paradigm of individualized treatment, is revolutionizing healthcare.

This article discusses current opportunities in precision neurology, focusing on key biomarkers that help with the differential diagnosis of neurologic conditions as well as stratification of subjects for clinical trials focusing on Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS) and related disorders.